BCBernard Candas

Bernard Candas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bernard Candas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Denis Talbot

    Department of Social and Preventive Medicine, Université Laval, Quebec City, Quebec, Canada

    2 shared publications
  • Awa Diop

    Département de médecine sociale et préventive, Université Laval, Québec, Canada; Centre de recherche du CHU de Québec, Université Laval, Québec, Canada

    1 shared publication
  • Benoit Cossette

    Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, Canada.

    1 shared publication
  • Caroline Sirois

    Centre de Recherche du CHU de Québec Université Laval Québec Québec Canada

    1 shared publication
  • Caroline Sirois

    Faculty of Pharmacy, Université Laval, Quebec City, Canada

    1 shared publication
  • Claude Labrie

    Oncology and Molecular Endocrinology Research Center, CHUL, Centre Hospitalier Universitaire de Québec and Laval University, Québec, Canada

    1 shared publication

Latest Publications

  • Open Access

    Evaluation and comparison of covariate balance metrics in studies with time‐dependent confounding

    by David Adenyo, Jason R. Guertin, Bernard Candas, Caroline Sirois, Denis Talbot

    Marginal structural models have been increasingly used by analysts in recent years to account for confounding bias in studies with time‐varying treatments. The parameters of these models are often estimated using inverse probability of treatment weighting. To ensure that the estimated weights adequately control confounding, it is possible to check for residual imbalance between treatment groups in the weighted data. Several balance metrics have been developed and compared in the cross‐sectional case but have not yet been evaluated and compared in longitudinal studies with time‐varying treatment. We have first extended the definition of several balance metrics to the case of a time‐varying treatment, with or without censoring. We then compared the performance of these balance metrics in a simulation study by assessing the strength of the association between their estimated level of imbalance and bias. We found that the Mahalanobis balance performed best. Finally, the method was illustrated for estimating the cumulative effect of statins exposure over one year on the risk of cardiovascular disease or death in people aged 65 and over in population‐wide administrative data. This illustration confirms the feasibility of employing our proposed metrics in large databases with multiple time‐points.


  • Open Access

    Effect of statin use for the primary prevention of cardiovascular disease among older adults: a cautionary tale concerning target trials emulation

    by Miceline Mésidor, Caroline Sirois, Jason Robert Guertin, Mireille E. Schnitzer, Bernard Candas, Claudia Blais, Benoit Cossette, Paul Poirier, James M. Brophy, Lisa Lix, et al.


  • Open Access

    Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice

    by Steeve Couillard, Claude Labrie, Sylvain Gauthier, Yves Merand, Shankar Mohan Singh, Bernard Candas, Fernand Labrie

    The antiproliferative effect of the new antiestrogen EM-800 has been studied during 40 weeks of treatment on human breast carcinoma ZR-75–1 xenografts in ovariectomized nude mice supplemented with estrone (0.5 μg, s.c. daily). At the daily 50 μg (approximately 2.5 mg/kg) oral dose, EM-800 caused a complete inhibition of the 680% stimulatory effect of estrone on the growth of the ZR-75–1 human breast cancer xenografts. Complete response, defined as the complete disappearance of the tumors, was observed in 41% of tumors following treatment with the 50 μg dose of the antiestrogen, while a value of 26% was found in ovariectomized animals. The proportion of tumors showing progression at the end of 40 weeks of treatment decreased from 94% in the estrone-supplemented animals to 62%, 61% and 19% in the animals receiving the 5 μg, 20 μg and 50 μg daily doses of the antiestrogen, respectively. None of the tumors that showed a complete or a partial response progressed at later time intervals. The 50 μg daily dose of EM-800 nearly completely (93%) or completely (28% below the value in ovariectomized animals) reversed the stimulatory effect of estrone on uterine and vaginal weight, respectively. The disappearance of 41% of tumors in the group of animals that received the 50 μg daily dose of EM-800 indicates that the antiestrogen induces cell death or apoptosis in ZR-75–1 human breast cancer cells and that its action is cytotoxic and not only cytostatic. Int. J. Cancer 83:424–429, 2000. ©2000 Wiley-Liss, Inc.